Related Experiment Videos
Mucosal leishmaniasis ("espundia" Escomel, 1911)
Summary
Espundia, a severe form of leishmaniasis, involves upper respiratory tract inflammation, often metastasizing from skin lesions. Current treatments, primarily pentavalent antimonials, are suboptimal for field use, necessitating targeted therapies.
Area of Science:
- Tropical Medicine
- Parasitology
- Infectious Diseases
Background:
- Espundia is a severe clinical manifestation of leishmaniasis, characterized by upper respiratory tract mucosal inflammation.
- This complication arises from metastasis of skin lesions caused by Leishmania braziliensis braziliensis (Lbb).
- Mucosal metastasis affects fewer than 5% of Lbb-infected patients, with determinants remaining largely unknown.
Purpose of the Study:
- To investigate the clinical presentation and treatment outcomes of espundia.
- To highlight the challenges in diagnosing and managing mucosal leishmaniasis.
- To emphasize the need for specific treatment strategies for espundia.
Main Methods:
- Observational study analyzing patient data with espundia.
- Review of clinical progression and treatment responses.
- Evaluation of diagnostic methods including leishmanin skin reaction and serological tests.
Main Results:
- Granulomas typically initiate on the nasal septum, with lesions extending to the pharynx, palate, larynx, and lips in some cases.
- Leishmania parasite isolation can be difficult, making serological and skin tests valuable for diagnosis.
- Pentavalent antimonials, while effective with regular dosing (low relapse rate), present challenges due to parenteral administration and toxicity.
Conclusions:
- Espundia is a rare but serious complication of leishmaniasis requiring specific therapeutic approaches.
- Current treatment with pentavalent antimonials, despite limitations, shows a low relapse rate when administered consistently.
- There is an unmet need for improved, field-friendly alternative treatments for espundia.